60 DEGREES PHARMA INC (SXTP) Stock News
NASDAQ:SXTP - Nasdaq - US83006G4010 - Common Stock - Currency: USD
SXTP Latest News, Press Relases and Analysis
Get insights into the top gainers and losers of Monday's after-hours session.
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
60 Degrees Pharma (SXTP) prices $5M public offering with potential $5M from warrant exercise; funds to support working capital and corporate purposes....
Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion
60 Degrees sets human babesiosis TAM for ARAKODA at $245M annually, $1.1B total through 2035; NDA planned for 2026 pending trial data. ...
60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
60 Degrees to seek FDA MUMS designation for tafenoquine in canine babesiosis, supported by 3 studies showing efficacy and safety in treating babesiosis....
60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Mentions: LBSR
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
60 Degrees launches 8-count ARAKODA® bottles, offering weekly malaria protection for short trips. Now available via major retail pharmacies....
Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals
Insurance claims show U.S. babesiosis incidence may be 10x CDC estimates; 60 Degrees links chronic fatigue and plans 2026 NDA for tafenoquine treatment....
60 Degrees Pharmaceuticals Announces First Quarter 2025 Results
60 Degrees Pharma reports Q1 2025 revenue up 55% to $163.6K, gross profit up 124%, driven by Arakoda sales....
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
Harrow (HROW) delivered earnings and revenue surprises of -2,000% and 19.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: HROW
Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases....
Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?
We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) stands against other stocks that fall behind amid market optimism. Wall Street’s main indices rebounded from hefty losses on Wednesday after President Donald Trump announced […]
Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
60 Degrees Pharma CEO Geoff Dow, PhD, will discuss babesiosis threats and therapies at the virtual Healing Lyme Summit, April 15–21...
Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited...
60 Degrees Pharmaceuticals Announces 2024 Annual Results
60 Degrees Pharmaceuticals (SXTP) reported 140% revenue growth in 2024, driven by Arakoda® sales. Clinical trials and market expansion efforts continue....
60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Mentions: FTHM
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
60 Degrees Pharma (SXTP) announces a 1-for-5 reverse stock split, effective Feb. 24, 2025, to meet Nasdaq's $1.00 minimum bid price requirement....
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
60 Degrees Pharma will import KODATEF® from Australia to ensure U.S. tafenoquine supply, addressing rising ARAKODA® demand....
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharma closed a $1.075M registered direct offering, raising $2.118M YTD to fund operations. H.C. Wainwright & Co. acted as placement agent....